Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Diversity and recognition efficiency of T cell responses to cancer.PLoS medicine · 2004
   Trial
2. OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.Frontiers in oncology · 2022
   Article
3. Immune reaction by cytoreductive prostatectomy.American journal of clinical and experimental urology · 2019
   Review
4. Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.Oncotarget · 2017
   Article
5. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
   Review
6. Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression.Oncogene · 2015
   Article
7. Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy.Molecular cancer · 2014
   Article
8. Adding fuel to the fire: immunogenic intensification.Human vaccines & immunotherapeutics · 2014
   Review
9. Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence.Journal of molecular medicine (Berlin, Germany) · 2013
   Article

Corrections and comments

• Comment on
  Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.2003

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as